Dirk Weber

1.1k citations

35 papers · 709 indexed · h-index 14

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment

Papers in ⓘ

Oncology 12
- HER2/EGFR in Cancer Research 5
- Cancer Treatment and Pharmacology 4
- Colorectal Cancer Treatments and Studies 4
Organic Chemistry 11
- Supramolecular Chemistry and Complexes 4

Co-authors: J. Tillner (8 shared papers)Frank Czubayko (1 shared paper)Anton Wellstein (1 shared paper)Hartmut Juhl (1 shared paper)Jack P. Antel (2 shared papers)C Berger (2 shared papers)Horst Kessler (3 shared papers)Peter Eickelmann (2 shared papers)
Journals: Journal of Clinical Oncology (11 papers)Annals of Oncology (3 papers)Molecular Cancer Therapeutics (1 paper)British Journal of Cancer (1 paper)Tetrahedron Letters (1 paper)
Partner nations: Germany United States Switzerland

In The Last Decade

Dirk Weber

33 papers receiving 682 citations

Peers

Countries citing papers authored by Dirk Weber

Since Specialization

Citations

This map shows the geographic impact of Dirk Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Weber more than expected).

Fields of papers citing papers by Dirk Weber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Weber. The network helps show where Dirk Weber may publish in the future.

Co-authors

The 25 scholars most cited alongside Dirk Weber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dirk Weber Line = papers co-authored together Dirk Weber links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer Journal of Clinical Oncology ·Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos, Duk‐Soo Bae, I Rzepka-Górska, Mariusz Bidziński, Giovanni Scambia, Svend Aage Engelholm, Florence Joly, Dirk Weber, Mona El-Hashimy, Jingjin Li, Farida Souami, P. Wing, Silke Engelholm, Aristotelis Bamias, Peter E. Schwartz	2012	95
2	Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer British Journal of Cancer ·Ullrich Graeven, B. Kremer, Th Südhoff, B. Killing, Federico Rojo, Dirk Weber, J. Tillner, Çağlar Ünal, Wolff Schmiegel	2006	83
3	A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) Annals of Oncology ·Christian Kollmannsberger, Marcus M. Schittenhelm, Friedemann Honecker, J. Tillner, Dirk Weber, Karin Oechsle, Lothar Kanz, Carsten Bokemeyer	2006	79
4	Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl₃-Promoted Silane Reduction of a β-Glycopyranoside Organic Letters ·Xiao‐jun Wang, Li Zhang, Denis Byrne, Larry J. Nummy, Dirk Weber, Dhileep Krishnamurthy, Nathan K. Yee, Chris H. Senanayake	2014	78
5	Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. PubMed ·Dirk Weber, H.-J. Klomp, Frank Czubayko, Anton Wellstein, Hartmut Juhl	2000	59
6	Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial Oncology ·Christoph Oehler, Karl Frei, Elisabeth J. Rushing, Paul M.J. McSheehy, Dirk Weber, Peter R. Allegrini, Dorothea Weniger, Urs M. Lütolf, Alexander Knuth, Yasuhiro Yonekawa, Krisztina Baráth, Angela Broggini‐Tenzer, Martin Pruschy, Silvia Höfer	2012	37
7	Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3 Journal of Medicinal Chemistry ·Dirk Weber, C Berger, Peter Eickelmann, Jack P. Antel, Horst Kessler	2003	37
8	A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a Annals of Oncology ·K.N. Chi, E. Beardsley, Bernhard J. Eigl, Peter Venner, Sébastien J. Hotte, E. Winquist, Yoo-Joung Ko, Srikala S. Sridhar, Dirk Weber, Fred Saad	2011	29
9	Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: An in vitro and in vivo study International Journal of Cancer ·Bence Sipos, Dirk Weber, Hendrik Ungefroren, Holger Kalthoff, Andre Zühlsdorff, Claudia Luther, Virág Török, Günter Klöppel	2002	29
10	Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin Journal of Clinical Oncology ·Rubén Niesvizky, Andrew Spencer, M. Wang, Dirk Weber, C. Chen, Meletios Α. Dimopoulos, Zhinuan Yu, Robert Delap, J. Zeldis, Robert Knight	2006	22
11	Systematic optimization of a lead‐structure identities for a selective short peptide agonist for the human orphan receptor BRS‐3 Journal of Peptide Science ·Dirk Weber, C Berger, Timo Heinrich, Peter Eickelmann, Jack P. Antel, Horst Kessler	2002	20
12	Phosphorylation of p-tert-butylthiocalix[4]arene: Reaction with phosphorus trichloride Tetrahedron Letters ·И. С. Антипин, Ivan I. Stoikov, А.Т. Губайдуллин, I.А. Litvinov, Dirk Weber, Wolf D. Habicher, A. I. Konovalov	1999	16
13	Phosphorylation of p-tert-butylthiacalix[4]arene: reaction with phosphorous triamides Journal of the Chemical Society Perkin Transactions 2 ·Dirk Weber, Маргит Грүнер, Ivan I. Stoikov, И. С. Антипин, Wolf D. Habicher	2000	15
14	Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma Journal of Clinical Oncology ·Stephen M. Rao, Naureen Starling, Mgbeosuru Benson, Alison Massey, A. Wotherspoon, Gina Brown, N. Anstice, J. Tillner, Dirk Weber, David Cunningham	2005	14
15	Unexpected differences in reactivity between tin and lead organyl chlorides – crystal structures of their organylphosphonium salts Inorganica Chimica Acta ·Dirk Weber, Sven H. Hausner, A. Eisengraber-Pabst, Sanghee Yun, J.A. Krause-Bauer, H. Zimmer	2003	12
16	First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. Journal of Clinical Oncology ·José Manuel Pérez García, Javier Cortés, Anastasios Stathis, Rogier Mous, Elena López-Miranda, Analía Azaro, Sofia Genta, Paolo Nucíforo, Ana Vivancos, Renata Ferrarotto, Francesco Bertoni, Davide Rossi, Nicole Spardy Burr, Oliver Schönborn‐Kellenberger, Karin Jorga, Laura Beni, Rajwinder Lehal, Michael Bauer, Dirk Weber, Elena Garralda	2018	9
17	A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies Journal of Clinical Oncology ·Takahiro Doi, Atsushi Ohtsu, N. Saijo, Hiroya Takiuchi, Y. Ohhashi, Dirk Weber, J. Tillner, Takao Sakata, Haibin Sun, Federico Rojo	2005	9
18	A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies Journal of Clinical Oncology ·Michael V. Seiden, H. A. Burris, U. Matulonis, James B. Hall, D. Armstrong, J Speyer, J. Tillner, Dirk Weber, Franco M. Muggia	2005	8
19	Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma Journal of Clinical Oncology ·Tanja Trarbach, N. Schleucher, Dirk Weber, J. Tillner, I. Fassmann, S. Seeber, U. Vanhoefer	2005	8
20	Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology ·Paul L. de Souza, Begoña Mellado, C. Pfister, Michael H. Rosenthal, Daniel Castellano, Dirk Weber, Sarah Ferrara, Noor Ahmad Shaik, Eugene Tan, Stephen G. Patterson	2010	6

About Dirk Weber

Dirk Weber is a scholar working on Oncology, Organic Chemistry, Reproductive Medicine, Immunology and Allergy and Pulmonary and Respiratory Medicine, having authored 35 papers that have together received 709 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers), Supramolecular Chemistry and Complexes (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Multiple Myeloma Research and Treatments (3 papers), Molecular Sensors and Ion Detection (3 papers) and Neuropeptides and Animal Physiology (3 papers). The work is most often cited by research in Oncology (305 citations), Reproductive Medicine (71 citations), Cell Biology (78 citations), Organic Chemistry (132 citations) and Cancer Research (66 citations). Dirk Weber has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include J. Tillner, Frank Czubayko, Anton Wellstein, Hartmut Juhl, Jack P. Antel, C Berger, Horst Kessler, Peter Eickelmann, Xiao‐jun Wang and Dhileep Krishnamurthy. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Molecular Cancer Therapeutics, British Journal of Cancer and Tetrahedron Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact